Oct 7, 2026

Dr. John Friend, CEO of Kazia Therapeutics, is investigating how to change the underlying biology that lets cancers resist treatment and evade the immune system. A central challenge in oncology is that cancer cells adapt and suppress immune recognition. Reprogramming the biology includes altering immune evasion...

Oct 7, 2026

Dr. John Friend, CEO of Kazia Therapeutics, is investigating how to change the underlying biology that lets cancers resist treatment and evade the immune system. A central challenge in oncology is that cancer cells adapt and suppress immune recognition. Reprogramming the biology includes altering immune evasion...

Sep 22, 2026

Eileen Heffernan, CEO and Co-Founder of Celltaxis, highlights that lymphedema is the most common lymphatic disorder and is a progressive chronic condition characterized by inflammation, fat deposition, and infections.  Currently there are no disease-modifying treatments available, requiring patients to rely on...

Sep 22, 2026

Eileen Heffernan, CEO and Co-Founder of Celltaxis, highlights that lymphedema is the most common lymphatic disorder and is a progressive chronic condition characterized by inflammation, fat deposition, and infections.  Currently there are no disease-modifying treatments available, requiring patients to rely on...

Aug 5, 2026

Lew Bender, Founder and CEO of Intensity Therapeutics, has developed a novel approach to treating solid tumors through direct intratumoral injection of existing chemotherapy drugs. The company uses a proprietary formulation containing a special molecule that makes water-based drugs soluble in fatty tissue, allowing...